Search Results

Embozene® Microspheres are indicated for the embolization of arteriovenous malformations and hypervascular tumors including uterine fibroids and hepatoma.

ONCOZENE™ Microspheres are indicated for the embolization of arteriovenous malformations and hypervascular tumors including hepatoma.

Embozene® Microspheres and ONCOZENE™ Microspheres are tightly calibrated, compressible microspheres intended to occlude vasculature for the purpose of blocking blood flow to a target tissue such as a hypervascular tumor (HVT) or arteriovenous malformation (AVM). The microspheres are manufactured from sodium polymethacrylate and coated with proprietary Polyzene®F. The microspheres are compressible to enable smooth delivery through the indicated delivery catheter. Embozene® Microspheres are available opaque or color coded by size to allow easy identification of the different sizes; ONCOZENE™ Microspheres are available in opaque only.

Embozene® / ONCOZENE™ Microspheres are supplied sterile and packaged in 20ml polycycloolefin syringes with a standard 7ml fill volume across the range. Embozene® Microspheres syringes or vials are available in 1 ml or 2 ml microsphere volume; ONCOZENE™ Microspheres are available in 2 ml or 3 ml microsphere volume.

The provided document is a 510(k) Summary of Safety and Effectiveness for CeloNova BioSciences' Embozene® Microspheres and ONCOZENE™ Microspheres. This document focuses on demonstrating substantial equivalence to existing predicate devices, rather than establishing acceptance criteria and proving new device performance against those criteria as would be typical for a novel device.

The core of this submission is an expanded indication for use to explicitly include "hepatoma" among the hypervascular tumors treated with these embolization devices. Therefore, the "acceptance criteria" here are implicitly related to the safety and effectiveness for this expanded indication, demonstrated by comparison to predicate devices and existing clinical data.

Here's an analysis based on your requested information:

1. Table of Acceptance Criteria and Reported Device Performance

Since this is a 510(k) for an expanded indication and not a de novo submission, there are no explicit, quantifiable "acceptance criteria" presented in the document in the format of a novel device performance study. Instead, the "acceptance criteria" are implied to be demonstration of substantial equivalence to legally marketed predicate devices, particularly regarding the safety and effectiveness for the embolization of hypervascular tumors, specifically hepatoma.

The "device performance" is primarily the finding that the subject devices are substantially equivalent to the predicate devices and that existing clinical data supports their safety and effectiveness for the expanded indication.

2. Sample Size Used for the Test Set and Data Provenance

• Test Set Sample Size: Not explicitly stated as a defined "test set" with a specific sample size. The clinical information reviewed included "published and unpublished data on the use of Embozene® for the treatment of hypervascular tumor including hepatoma (outside the United States) and postmarket experience with the cleared device." The exact number of patients or cases in this cumulative "test set" is not provided.
• Data Provenance: The data provenance mentioned is "outside the United States" for the use of Embozene® for hepatoma, and general "postmarket experience" with the cleared devices. This suggests a mix of retrospective (published studies, postmarket reports) and potentially some prospective data if "unpublished data" includes ongoing registries or smaller studies.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

The document does not specify the number or qualifications of experts used to establish a "ground truth" for a specific test set. The clinical information reviewed was "published and unpublished data" and "postmarket experience," implying that the assessment of safety and effectiveness relied on existing medical literature and real-world usage data, which inherently includes diagnoses and outcomes established by medical professionals in various clinical settings.

4. Adjudication Method for the Test Set

No explicit adjudication method is mentioned. The review seems to be a synthesis of existing literature and postmarket surveillance rather than a specific study with a defined adjudication process.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No, an MRMC comparative effectiveness study was not done. This submission is for an expanded indication based on substantial equivalence and a review of existing data, not for a comparative effectiveness study of human readers with or without AI assistance.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

This question is not applicable. The device is a medical product (microspheres for embolization), not an algorithm or AI.

7. The Type of Ground Truth Used

The "ground truth" for demonstrating safety and effectiveness for hepatoma embolization was based on the outcomes data and findings reported in published and unpublished clinical studies, as well as postmarket surveillance data. This includes diagnoses by clinicians, treatment effectiveness, and adverse events.

8. The Sample Size for the Training Set

This question is not applicable. The device is a medical product, not an AI or algorithm that requires a "training set." The submission relies on existing clinical evidence, not a machine learning model.

9. How the Ground Truth for the Training Set Was Established

This question is not applicable for the reasons mentioned above.

Ask a specific question about this device

Embozene® Microspheres are intended for embolization of hypervascular tumors and arteriovenous malformations.

Embozene® Microspheres are tightly calibrated, compressible microspheres intended to occlude vasculature for the purpose of blocking blood flow to a target tissue such as hypervascular tumor (HVT) or arteriovenous malformation (AVM). Embozene® Microspheres are manufactured from sodium polymethacrylate and coated with proprietary Polyzene®-F. The microspheres are compressible to enable smooth delivery through the indicated delivery catheter. Embozene® Microspheres are color coded by size to allow easy identification of different sizes. Embozene® Microspheres are supplied sterile and packaged in 20ml polycycloolefin syringes with a standard 7ml fill volume across the range. Embozene® Microspheres syringes and vials are available with 1 ml or 2 ml microsphere volume per syringe or vial.

This document is a 510(k) summary for Embozene® Microspheres, describing their intended use, device description, and a comparison to a predicate device. It does not describe a study involving an AI device or a direct performance evaluation against acceptance criteria in the context of AI/ML. Instead, it focuses on demonstrating substantial equivalence to a previously cleared device.

Therefore, many of the requested elements for an AI device study are not present in the provided text. I will answer based on the information available and indicate when information is not extractable from the provided text.

1. A table of acceptance criteria and the reported device performance

The provided text describes a submission for demonstrating substantial equivalence for an existing device, Embozene® Microspheres, with the addition of new sizes (1100 µm and 1300 µm). It does not present acceptance criteria for a "device performance" in the typical sense of accuracy, sensitivity, or specificity as might be seen for an AI/ML device.

Instead, the "performance" here relates to demonstrating that the new sizes of the Embozene® Microspheres maintain the same characteristics and safety profile as the predicate device. The implicit acceptance criteria are that the new sizes are substantially equivalent to the cleared predicate device.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

This information is not applicable in the context of the provided document. The submission is for a medical device (microspheres), not an AI/ML diagnostic or prognostic tool that would typically use a test set of data. The "clinical evaluation" mentioned in Section 8 refers to a review of existing literature and post-market surveillance, not a specific prospective or retrospective study with a defined sample size for the purpose of validating an algorithm.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This information is not applicable. The document describes a medical device, not an AI/ML algorithm that requires expert-established ground truth on a test set. The clinical evaluation process relies on existing scientific literature, a broad assessment by medical professionals, and regulatory review processes, rather than a specific number of experts labeling data for a test set.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

This information is not applicable for the same reasons as points 2 and 3.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This information is not applicable. This document is a 510(k) summary for a medical device (microspheres), not an AI/ML device, and thus no MRMC study or AI assistance evaluation was conducted or reported here.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This information is not applicable. This document is a 510(k) summary for a medical device (microspheres), not an AI/ML device.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

For the purpose of this 510(k) submission, the "ground truth" concerning the safety and effectiveness of the Embozene® Microspheres (including the new sizes) is established through:

• Engineering and material characterization: In-vitro testing for size distribution and catheter compatibility (Section 7). This confirms the physical properties.
• Scientific literature review: A comprehensive review of Transarterial Embolization (TAE) using various embolic agents, including the existing Embozene® Microspheres, over the last ten years (Section 8). This constitutes a form of aggregated "outcomes data" and medical consensus from the broader scientific community.
• Unpublished data and post-market surveillance: This also contributes to the "outcomes data" and real-world evidence confirming the safety and effectiveness of the existing device family (Section 8).

There is no "ground truth" established for an AI algorithm's performance.

8. The sample size for the training set

This information is not applicable. This is not an AI/ML device.

9. How the ground truth for the training set was established

This information is not applicable. This is not an AI/ML device.

Ask a specific question about this device